Drug Trial Radar · NCT02889796
Filgotinib in Combination With Methotrexate in Adults With Moderately to Severely Active Rheumatoid Arthritis Who Have an Inadequate Response to Methotrexate
Last checked: Nov 19, 2026Latest source record: Jun 9, 2021 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
1,759
Actual
Start
Aug 30, 2016
Primary completion
Jul 4, 2018
Study completion Jun 20, 2019
Sponsor
- Lead sponsor
- Gilead SciencesGilead Sciences (GILD)
- Sponsor type
- Industry
- Collaborators
- Lakefront Biotherapeutics NV
- First posted
- Sep 7, 2016
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The primary objective of this study is to evaluate the effects of filgotinib versus placebo for the treatment of signs and symptoms of rheumatoid arthritis (RA) as measured by the percentage of participants achieving an American College of Rheumatology 20% improvement response (ACR20) at Week 12.
Conditions
- Rheumatoid Arthritis
Interventions
FilgotinibDrug
200 mg or 100 mg tablet(s) administered orally once daily
Placebo to match filgotinibDrug
Tablet(s) administered orally once daily
AdalimumabDrug
40 mg administered via subcutaneous injection once every two weeks
Placebo to match adalimumabDrug
Administered via subcutaneous injection once every two weeks
MTXDrug
Commercially sourced tablet(s) administered orally
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of Participants Who Achieved an American College of Rheumatology (ACR) 20% Improvement (ACR20) Response at Week 12Time frame: Week 12
Locations
230 sites in 30 countries. Site status is shown where the registry gives one.
Site not named
Huntsville, Alabama
Site not named
Phoenix, Arizona
Site not named
Tucson, Arizona
Site not named
Covina, California
Site not named
Hemet, California
Site not named
La Jolla, California
Site not named
Palm Desert, California
Site not named
Upland, California
Site not named
Victorville, California
Site not named
Whittier, California
Site not named
Clearwater, Florida
Site not named
DeBary, Florida
Site not named
Jacksonville, Florida
Site not named
Miami, Florida
Site not named
Miami Lakes, Florida
Site not named
New Port Richey, Florida
Site not named
Orlando, Florida
Site not named
Plantation, Florida
Site not named
Kansas City, Kansas
Site not named
Wichita, Kansas
Site not named
Elizabethtown, Kentucky
Site not named
Lexington, Kentucky
Site not named
Cumberland, Maryland
Site not named
Hagerstown, Maryland
Site not named
Wheaton, Maryland
Site not named
Detroit, Michigan
Site not named
Saint Clair Shores, Michigan
Site not named
Eagan, Minnesota
Site not named
Hattiesburg, Mississippi
Site not named
Tupelo, Mississippi
Site not named
St Louis, Missouri
Site not named
Toms River, New Jersey
Site not named
Albuquerque, New Mexico
Site not named
Salisbury, North Carolina
Site not named
Bethlehem, Pennsylvania
Site not named
Duncansville, Pennsylvania
Site not named
Philadelphia, Pennsylvania
Site not named
Wyomissing, Pennsylvania
Site not named
Charleston, South Carolina
Site not named
Columbia, South Carolina
Showing 40 of 230 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.